VFEND 200 MG POWDER FOR SOLUTION FOR INFUSION

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

VORICONAZOLE 200 MG/VIAL

Commercializzato da:

PFIZER PHARMACEUTICALS ISRAEL LTD

Codice ATC:

J02AC03

Forma farmaceutica:

POWDER FOR SOLUTION FOR INFUSION

Via di somministrazione:

I.V

Prodotto da:

PFIZER PGM, FRANCE

Gruppo terapeutico:

VORICONAZOLE

Indicazioni terapeutiche:

Treatment of : - invasive aspergillosis fluconazole-resistant serious invasive Candida infections (including C. krusei), - serious fungal infections caused by scedosporium spp. and fusarium spp.Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. Treatment of candidemia in non neutropenic patients.

Data dell'autorizzazione:

2012-10-01